AUA 2011 - Activation of cannabinoid receptor 2 inhibits experimental cystitis - Session Highlights

WASHINGTON, DC USA (UroToday.com) - Two experimental studies related to therapy caught my eye. Dale Bjorling and co-investigators from Madison, Wisconsin investigated whether activation of cannabinoid receptor 2 (CB2) alters severity of experimental cystitis induced by acrolein and referred hyperalgesia associated with cystitis.

A selective CB2 agonist reduced severity of cystitis and inhibited bladder inflammation-induced increased peripheral sensitivity to mechanical stimuli.

Brian Birch and colleagues from Southampton, UK found that most honeys contain a constituent that inhibits spontaneous and stimulated mast-cell degranulation in a cell line model. They discussed the possibility of its use alone or as a part of an intravesical cocktail for treatment of the condition.

 

 

Presented by Dale Bjorling , et al. at the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA

Also: The effect of honey on mast-cell degranulation: a possible role in painful bladder syndrome/interstitial cystitis (PBS/IC)
presented by Brian Birch, et al.



Reported for UroToday by Philip M. Hanno, MD, MPH, Professor of Urology in the Division of Urology at the Hospital of the University of Pennsylvania.


 

The opinions expressed in this article are those of the UroToday.com Contributing Editor and do not necessarily reflect the viewpoints of the American Urological Association.


 

 



View Full AUA 2011 Meeting Coverage